Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
Launched by UNIVERSITY OF COLORADO, DENVER · Feb 18, 2014
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women age ≥ 18
- • Desire for immediate postpartum IUD or postpartum day #1 after a postplacental IUD placement
- • English or Spanish speaking
- • Willing to attend 2 follow-up visits
- Exclusion Criteria:
- • Multiple gestations
- • Delivery prior to 35 weeks gestational age
- • Allergy or sensitivity to any component of either IUD (including polyethylene, levonorgestrel or copper)
- • Cesarean delivery
- • Postpartum hemorrhage (estimated blood loss \> 500 mL)
- • Chorioamnionitis
- • Abnormal uterine anatomy (including uterine anomaly or large fibroids)
- • Treated for Chlamydia or Gonorrhea during pregnancy without a subsequent negative follow-up test
- • Current cervical cancer or carcinoma in situ
- • Current breast cancer
- • Wilson's disease
- • If enrolling postpartum after IUD has already been placed, women will be excluded if the provider used an insertion technique other than using the ring forceps or the operator's hand
Trial Officials
Stephanie Teal, MD
Principal Investigator
University of Colorado, Denver
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials